Trial
NCT02477787
Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk AML and MDS
Phase IITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Asan Medical Center
Collaborators
—
Condition
Acute Myelogenous Leukemia
Intervention
allogeneic, donor-derived NK cells
Why stopped
upon recommendation from the Data Monitoring Committee
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-07-08